It is promising that gene therapy (e.g., voretigene neparvovec-rzyl) is already commercially available for subretinal injection for RPE65-associated Leber’s congenital amaurosis (LCA) [34], and other retinal dystrophies, such as choroideremia, achromatopsia and retinitis pigmentosa are being treated with subretinal gene therapy in phase I/II clinical trials, despite also having retinal fragility [35–38]. This evidence concerns the gene RPE65 and retinitis pigmentosa.